Nasdaq:US$16.79 (+0.96) | HKEX:HK$25.75 (+0.70) | AIM:£2.67 (+0.07)
News & Presentations
Previous Article   |   Next Article
Presentations, Scientific Publications | 16 Oct 2010

ISSX 2011: Preclinical assessment of the absorption, distribution, metabolism and excretion of HMPL-013 (fruquintinib), a novel potent and specific VEGFR inhibitor